{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-076136","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2023-06-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.964923+00:00","generated_at":"2026-06-13T14:49:16.904369+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Immunome merges with Morphimmune; Siegall new CEO; $125M PIPE at $5.75/share","bullets":["Morphimmune stockholders to own ~45% of combined company; Immunome stockholders ~55% on fully diluted basis.","Clay Siegall to become Chairman and CEO; board to include 2 from Morphimmune, 1 from Immunome, 4 independents.","PIPE financing of ~$125M at $5.75/share (or $5.91 for affiliates) from Enavate, EcoR1, Redmile.","Siegall employment agreement: $650K base, 50% bonus target, option for 2.14M shares at $5.91.","Closing conditions include S-4 effectiveness, Nasdaq listing, PIPE proceeds of $125M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-076136","json":"https://secwatch.observer/filing/0001104659-23-076136.json","markdown":"https://secwatch.observer/filing/0001104659-23-076136.md","text":"https://secwatch.observer/filing/0001104659-23-076136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923076136/0001104659-23-076136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923076136/tm2320045d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T14:49:16.904369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"267b416992d3cdaed7a774a56da36e1b4809fa67","claim":"Immunome Inc. entered into Agreement and Plan of Merger and Reorganization with Morphimmune Inc. (effective 2023-06-29).","evidence_excerpt":"On June 29, 2023, Immunome, Inc., a Delaware corporation (“Immunome”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Morphimmune Inc., a Delaware corporation (“Morphimmune”), a biotechnology company focused on developing targeted oncology therapeutics, and Ibiza Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Immunome (“Merger Sub”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923076136/0001104659-23-076136-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Morphimmune Inc."},{"label":"Effective","value":"2023-06-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}